Additional Relevant Details An oral presentation and a poster at the AARC Annual Meetingwill highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively.  According to the VP, the "data provides additional preclinical support for initiating clinical trials of GMI-1359 in both FLT3 mutated AML and pancreatic cancer."